It is more than quiet here. It is dead! I guess we are all waiting for some news.
Here is a post by neuroinv on the Yahoo thread:
"You may need to reread your issues, since Interneuron is discussed on p. 2 and 4 in June, 2 and 3 in May. While I do make 180 degree turns on stock recommendations when warranted (e.g.Cephalon) I have no reason to shift my view of IPIC; If one takes a crude book valuation as of the end of 2Q, IPIC is worth 2.64 per share. This is before one grants any value to pagoclone, CerAxon, Bextra. Or anything earlier on, like PACAP, or the OTC products, like PMS Escape. Pagoclone is the kind of anxiolytic many companies have been trying to develop, while CerAxon (now that lubeluzole is dead) is still likely to be the first useful drug to be approved for stroke (since tPA is only applicable to 5% of stroke patients, I do not consider it clinically all that useful). Those two drugs each have billion dollar potential; that is only potential as of yet, but essentially today's price values them together as being worth a dollar per share or less (i.e. under 40 million total). That is an absurd undervaluation.
This is before one comes to Bextra, and it is the fact that the BEST trial has not yet come to a close, and there have been news reports questioning the mortality impact of older generation beta blockers, which have caused InterCardia and Interneuron to both slide precipitously. The continuation of the Bextra trial may indicate that it does not have 'blockbuster' magnitude of effect, but no bymeans have we reached a point where one should assume no benefit, that Bextra is not a potential competitor to Coreg. Another factor that greased the skids was the fall below marginable limits; I suspect that short sellers successfully drove down the price, then forcing margined accounts to sell off in turn. The accurate report that followup Redux studies are also taking longer than expected to enroll enough patients further worries observers ( the Cosmetic Surgeon report cited in a post on this thread just means that they are 'operating' on old amd/or vague information). It will take until August (pagoclone, perhaps the next two Redux studies) for IPIC to have distinctly positive news. I continue to expect that between August and the end of the year, that Interneuron will rebound very strongly. NeuroInvestment (www.neuroinv.com)".
|
